Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths (or nearly one in six) in 2020 [1].Therapeutic drugs for cancer remain under continuous development. Among these, tyrosine kinases play a pivotal role in cellular processes such as growth, development, and differentiation. Their dysregulation is closely associated with the onset and progression of various diseases, particularly cancer [2].The primary mechanism of tyrosine kinases involves phosphorylating tyrosine residues on substrate proteins, thereby activating downstream signaling pathways to regulate vital cellular processes such as growth, proliferation, differentiation, migration, and survival [3]. Based on structural and functional characteristics, they are classified into receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases [4]. Receptor tyrosine kinases reside on the cell membrane surface, serving as vital mediators for cellular signaling exchanges with the external environment. They comprise an extracellular ligand-binding domain, a single transmembrane domain, and a cytoplasmic kinase domain. Upon ligand binding to the extracellular region, the receptor dimerizes, activating the tyrosine kinase activity within the cytoplasmic kinase domain, thereby initiating downstream signaling pathways [5]. Non-receptor tyrosine kinases lack transmembrane domains and reside primarily in the cytoplasm, yet they play indispensable roles in cellular signaling.